Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $13.25.

Several equities research analysts recently commented on the company. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Clear Str raised Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Stifel Nicolaus started coverage on Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 target price for the company. Finally, B. Riley Financial started coverage on Palisade Bio in a report on Friday, January 9th. They set a “buy” rating and a $7.00 price target on the stock.

Palisade Bio Price Performance

PALI opened at $1.99 on Tuesday. The firm has a market capitalization of $296.51 million, a price-to-earnings ratio of -0.94 and a beta of 1.53. The company’s 50 day simple moving average is $1.77 and its two-hundred day simple moving average is $1.68. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.64.

Hedge Funds Weigh In On Palisade Bio

A number of institutional investors have recently bought and sold shares of the company. Cetera Investment Advisers purchased a new stake in shares of Palisade Bio in the 4th quarter valued at approximately $25,000. Seven Fleet Capital Management LP purchased a new stake in shares of Palisade Bio during the 4th quarter valued at approximately $770,000. Perceptive Advisors LLC acquired a new position in Palisade Bio in the fourth quarter valued at approximately $28,318,000. Commodore Capital LP acquired a new position in Palisade Bio in the fourth quarter valued at approximately $26,896,000. Finally, Eversept Partners LP purchased a new position in Palisade Bio in the fourth quarter worth approximately $12,670,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.